Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

TCR2 closes $125mm Series B round

Executive Summary

TCR2 Therapeutics Inc. (immuno-oncology) raised $125mm through its Series B round. Curative Ventures and 6 Dimensions Capital co-led and were joined by additional new investors Redmile Group, ArrowMark Partners, Hillhouse Capital Group, Mirae Asset Financial Group, Syno Capital, Haitong International Securities, Lucion Group, Sirona Capital, Alexandria Venture Investments, and affiliates of Leerink Partners. Existing investors MPM Capital, F2 Ventures, and Cathay Fortune Capital Investment also participated.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register